Treatment of cancer with immunomodulators.
D000818:Animals; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000494:pharmacology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007115:Immunization Schedule; D007167:Immunotherapy / Q000009:adverse effects; D007978:Levamisole / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008264:Macrophages / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology; D011425:Propionibacterium acnes / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000494:pharmacology*
D000942:Antigens, Bacterial; D014613:Vaccines, Attenuated; D007978:Levamisole